GuruTrack
BDX

BDX

BECTON DICKINSON AND CO

Data as of 2026 Q2 (06-30) · 13F snapshot

Summary
BECTON DICKINSON AND CO (BDX) is held as common stock by 4 tracked hedge-fund managers, with a combined reported value of ~$77.53M; the largest are Joel Greenblatt, Ken Griffin, Jeremy Grantham. 3 tracked managers also disclosed PUT or CALL positions, reported separately below. This quarter: 2 added, 2 trimmed, 3 closed. 20 public STOCK Act / OGE trade disclosures are on record. Data as of 2026 Q2, from public SEC 13F filings, delayed up to ~45 days.
Attention · MediumThis quarter · Cooling
Common-stock holders43 also report options
Congress trades20
Price$183.83vs quarter-end+21.48%
Sectors1
This quarter's moves
New0
Added2
Trimmed / sold5
Top holderJoel Greenblatt

Common-stock positions

PUT and CALL disclosures are excluded from these holder counts and values.

PUT / CALL disclosures

Reported separately: 13F option values are not common-stock ownership and do not reveal the full strategy or economic exposure.

Ken GriffinPUT—
Value $17.84M— of portfolio117,9002026 Q2
Ken GriffinCALL—
Value $7.91M— of portfolio52,3002026 Q2
Steven CohenCALL—
Value $938.2K— of portfolio6,2002026 Q2
Paul Tudor JonesCALL—
Value $378.3K— of portfolio2,5002026 Q2
Steven CohenPUT—
Value $15.1K— of portfolio1002026 Q2

Insider Trading

Officers · directors · Form 4
Open-market purchases and sales (P/S)10

  • Thomas E Polen Jr

    Chairman, CEO and President

    Sell$768.1K
    4,152 @ $185.00Traded 2026-08-13Filed 2026-08-14

  • Roland Goette

    EVP and President, EMEA

    Sell$440.9K
    2,438 @ $180.84Traded 2026-08-11Filed 2026-08-12

  • Michael Feld

    EVP, Chief Revenue Officer

    Sell$11.8K
    75 @ $157.13Traded 2026-07-27Filed 2026-07-28

  • Michael Feld

    EVP, Chief Revenue Officer

    Sell$11.5K
    75 @ $152.80Traded 2026-06-26Filed 2026-06-26

  • Michael David Garrison

    EVP & Pres Med.Essntl&BioPharm

    Sell$160.2K
    1,100 @ $145.66Traded 2026-06-24Filed 2026-06-25

  • Michael David Garrison

    EVP & Pres Med.Essntl&BioPharm

    Sell$166.6K
    1,100 @ $151.48Traded 2026-06-10Filed 2026-06-11

  • Thomas E Polen Jr

    Chairman, CEO and President

    Sell$404.5K
    2,764 @ $146.35Traded 2026-06-01Filed 2026-06-03

  • Michael Feld

    EVP, Chief Revenue Officer

    Sell$11.1K
    75 @ $147.35Traded 2026-05-26Filed 2026-05-27

  • Michael Feld

    EVP, Chief Revenue Officer

    Sell$11.2K
    74 @ $151.94Traded 2026-04-27Filed 2026-04-28

  • Michael Feld

    EVP, Chief Revenue Officer

    Sell$11.8K
    75 @ $156.83Traded 2026-03-26Filed 2026-03-27

Insider transactions are public SEC Form 4 disclosures (company officers, directors, 10% owners), for research only — not investment advice.

Public SEC 13F filings may appear up to 45 days after quarter-end; STOCK Act / OGE trade filings are generally due within 45 days but may be late. Partial data only — research, not investment advice.